Compare LII & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LII | NTRA |
|---|---|---|
| Founded | 1895 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 27.0B |
| IPO Year | 1999 | 2015 |
| Metric | LII | NTRA |
|---|---|---|
| Price | $511.08 | $244.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $605.18 | $227.69 |
| AVG Volume (30 Days) | 451.7K | ★ 1.7M |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 12.46 | N/A |
| EPS | ★ 23.67 | N/A |
| Revenue | ★ $5,345,300,000.00 | $2,116,676,000.00 |
| Revenue This Year | N/A | $32.77 |
| Revenue Next Year | $7.34 | $16.51 |
| P/E Ratio | $21.62 | ★ N/A |
| Revenue Growth | 3.77 | ★ 38.17 |
| 52 Week Low | $443.19 | $125.38 |
| 52 Week High | $689.44 | $245.59 |
| Indicator | LII | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.54 | 80.03 |
| Support Level | $481.60 | $233.67 |
| Resistance Level | $499.95 | $240.18 |
| Average True Range (ATR) | 14.23 | 7.39 |
| MACD | 6.58 | 0.68 |
| Stochastic Oscillator | 99.78 | 97.49 |
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.